DO-BO

How Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?

What does it take to succeed in Market Access? In this brand new episode of MAP, the Market Access podcast, Dr. Stefan Walzer sits down with industry veteran Adrian Kielhorn, co-author of The Market Access Guide. Together, they unpack the evolving role of market access professionals, the power of strategic thinking, mastering negotiations, and why patient centricity is key to success.

Learn how to develop a strong value story, navigate pricing and reimbursement, and stay ahead in the dynamic pharmaceutical and healthcare landscape. Whether you’re a seasoned professional or just starting out, this episode is packed with insights, strategy, and a touch of humor to help you navigate the ever-changing market access landscape. Tune in now for expert insights on the future of market access & health economics!

Related

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]